NCT00004196View on ClinicalTrials.gov

Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis

PHASE3CompletedINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

October 31, 1999

Primary Completion Date

October 31, 2004

Study Completion Date

November 30, 2007

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

recombinant interferon alfa

PROCEDURE

lymphangiography

DRUG

Observation

Trial Locations (4)

40202

James Graham Brown Cancer Center at University of Louisville, Louisville

35294-3300

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

08903

Cancer Institute of New Jersey, New Brunswick

14263-0001

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Alabama at Birmingham

OTHER

NCT00004196 - Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis | Biotech Hunter | Biotech Hunter